A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit in Patients with Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - August 5, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-OV60/GOG-3052/RAMP 201 study Source RELATED ARTICLESMORE FROM AUTHOR Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer MOST POPULAR Significant Interaction Between a Chemotherapy Benefit and Menopausal Status Found in... December 7, 2021 Elderly Woman Seeks Trick-Or-Treaters Who Surprised Her With Gifts The Day... November 12, 2021 Stress-Induced Immune Changes May Help Cancer Spread April 2, 2024 Connecting and Celebrating December 23, 2020 Load more HOT NEWS Antitumour Activity and Favourable Safety Demonstrated After Treatment with Nivolumab and... Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in... Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... FDA Approves Ivosidenib for Myelodysplastic Syndromes
